What are some key supply considerations that sponsors need to keep in mind when planning a DCT? What should they look out for when choosing a supply partner?
He talks to us about key developments in the inhalation industry and how the formation of a leading global CDMO can provide support in navigating these changes.
Worth $14 million, entails providing project management and administrative oversight as the IRB of record for Biorepository Protocol and NIAID studies.
Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.
Margrethe Sørgaard offers 25 years’ experience in leading positions in clinical development and operation, medical affairs and drug safety/pharmacovigilance.
This webinar on May 1 will explore several alternative clinical supply models, use cases and identify key considerations when adopting one of these models.